Legend Biotech Corp (LEGN) Stock: What Does the Chart Say Wednesday?

The market has been high on Legend Biotech Corp (LEGN) stock recently. LEGN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Legend Biotech Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LEGN!

See Full LEGN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With LEGN Stock Today?

Legend Biotech Corp (LEGN) stock is up 0.95% while the S&P 500 is lower by -0.03% as of 1:48 PM on Wednesday, Dec 7. LEGN has gained $0.51 from the previous closing price of $53.96 on volume of 781,197 shares. Over the past year the S&P 500 is lower by -14.19% while LEGN has gained 21.04%. LEGN lost -$2.34 per share in the over the last 12 months. To screen for more stocks like Legend Biotech Corp click here.

More About Legend Biotech Corp

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. Click Here to get the full Stock Report for Legend Biotech Corp stock.